Does Blue Cross Blue Shield (Federated) Cover AndroGel?

How BCBS Federated Plans Are Structured and Why Coverage Varies

Blue Cross Blue Shield (Federated) is not a single insurer. Each state's BCBS licensee sets its own formulary independently, which means a member in Texas may face different tier placement than a member in Illinois, even within the same employer group. The Federal Employee Program (FEP), administered separately by the BCBS Association, maintains its own national formulary that also differs from commercial state plans. Because of this structure, there is no single nationwide answer to whether AndroGel is covered. Coverage depends on the specific plan code, plan year, and state of enrollment.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism defines the condition as "a clinical syndrome that results from failure of the testis to produce physiological concentrations of testosterone," and recommends testosterone therapy only when serum testosterone is consistently below the lower limit of the normal range, typically 300 ng/dL for most U.S. laboratory reference ranges [1]. BCBS medical policies across most state plans align directly with this threshold. Plans that follow the Endocrine Society language require two fasting morning testosterone measurements taken on separate days before approving any testosterone replacement, including AndroGel [1].

Testosterone deficiency affects an estimated 2.1% to 3.8% of men in U.S. population studies, though rates rise sharply after age 60 [2]. The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011, both specifically for male hypogonadism due to primary or secondary causes [3]. Neither formulation carries an FDA approval for weight loss, fat redistribution, or athletic performance, and BCBS plans will deny claims filed under those indications.

Prior Authorization Criteria for AndroGel on BCBS Federated Plans

Prior authorization (PA) is required for AndroGel on the vast majority of BCBS Federated commercial and FEP plans. The PA submission must come from the prescribing physician and must document specific clinical criteria. Missing even one criterion is the most common reason for first-round denial.

Standard PA criteria seen across BCBS Federated state plans include: a confirmed diagnosis of male hypogonadism (ICD-10 E29.1 for primary or E23.0 for secondary), two serum total testosterone values below 300 ng/dL drawn before 10 a.m. on separate days, documentation of signs or symptoms consistent with hypogonadism (such as reduced libido, fatigue, decreased bone density, or loss of muscle mass), and confirmation that the patient does not have a contraindication to testosterone therapy such as prostate cancer or a hematocrit above 54% [4].

The American Urological Association's 2018 guidelines on testosterone deficiency state that "testosterone therapy is not recommended for men who are actively trying to father children" and that baseline prostate-specific antigen (PSA) should be checked before initiation [4]. BCBS PA forms frequently mirror this language and will ask for a recent PSA result (typically within the past 12 months) and a documented discussion of fertility implications.

For FEP plans specifically, the BCBS FEP 2024 pharmacy formulary places brand-name AndroGel at a higher cost-sharing tier than generic testosterone gel. Members can download the FEP formulary drug list at OPM.gov or through the FEP BlueRx portal to confirm exact tier placement for the current plan year [5].

Step Therapy: What BCBS Requires Before Approving AndroGel

Step therapy is the biggest source of initial denials for AndroGel on BCBS Federated plans. Most plans require that a patient try and fail at least one lower-cost testosterone formulation before approving the brand-name gel. Generic testosterone gel (1% or 1.62%), testosterone cypionate injection (200 mg/mL), and testosterone enanthate injection are the agents most commonly listed as required first-line steps [6].

A step therapy trial is typically defined as a minimum 30-to-90-day course, accompanied by follow-up serum testosterone levels demonstrating either inadequate response (testosterone remaining below 300 ng/dL) or documented intolerance. Intolerance must be specific. "Patient preference" alone does not satisfy most BCBS step criteria. Documented adverse effects such as injection-site reactions, skin irritation from a competing generic gel formulation, polycythemia, or a needlephobia that is clinically verified may be accepted as step-therapy failure [6].

Generic testosterone gel typically costs $30 to $60 per month at retail pharmacies, compared to approximately $510 per month for brand-name AndroGel before any insurance adjustment [7]. The large cost differential is the explicit reason insurers require the step. If a patient tolerates generic testosterone gel at the same dose and achieves target serum testosterone (generally 400-700 ng/dL as recommended by the Endocrine Society [1]), the plan has no clinical basis to approve the brand-name product at a higher cost.

Testosterone cypionate injection at 100-200 mg every 1-2 weeks remains the lowest-cost option and is the most commonly mandated first step on employer-sponsored BCBS plans. A 10-mL multidose vial of testosterone cypionate 200 mg/mL (enough for approximately 10 weeks of therapy at 100 mg/week) costs under $50 at most pharmacies without insurance [7].

Formulary Tier Placement and What It Means for Your Copay

Formulary tier placement determines out-of-pocket cost. Across BCBS Federated commercial plans, AndroGel 1% and 1.62% typically land on Tier 3 (non-preferred brand) or Tier 4 (specialty brand), depending on the plan design. Tier 3 copays generally run $60-$100 per 30-day supply after the deductible is met. Tier 4 or specialty tier placement can push member cost-share to 25%-40% coinsurance, which on a $510 list-price drug means $127-$204 per month even with active insurance [8].

A 2020 analysis published in JAMA Internal Medicine found that formulary tier placement for branded testosterone products varied substantially across commercial insurers, and that tier changes mid-year were a common driver of treatment discontinuation [9]. For BCBS specifically, the formulary is typically locked for the plan year starting January 1, but exceptions occur when a drug's contract status changes mid-year.

The practical implication: check the exact formulary for your specific plan ID, not just the general BCBS brand. Two employees at the same company may have BCBS coverage through different plan codes and face different tiers for the same drug. The BCBS member portal or a call to the pharmacy benefits line (the number on the back of the insurance card) will confirm current tier placement within minutes [5].

Clinical Evidence Supporting AndroGel Prescriptions That Insurers Accept

Insurance companies use published clinical evidence and FDA-approved labeling to write their medical necessity policies. Submitting a PA that cites the right trials directly can strengthen the case.

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 or older with serum testosterone below 275 ng/dL, found that testosterone treatment for one year significantly improved sexual function, physical function, and bone mineral density compared to placebo [10]. The sexual function trial showed a mean improvement in the PDSS score of 2.64 points in the testosterone group vs. 0.59 in placebo (P<0.001) [10]. The bone trial showed a 7.5% mean increase in volumetric bone mineral density at the spine in the testosterone group [10]. These T-Trials results, published in the New England Journal of Medicine in 2016, are the most frequently cited data set in BCBS medical necessity policies for testosterone therapy [10].

A 2013 systematic review in the Annals of Internal Medicine covering 156 trials found that testosterone therapy in hypogonadal men consistently improved sexual function scores but that evidence for cardiovascular outcomes remained mixed [11]. BCBS PA criteria often include a cardiovascular risk assessment requirement, citing this evidence gap. The prescribing physician should document baseline blood pressure, hematocrit, lipid panel, and PSA in the PA submission to preempt a request for additional information [4].

The FDA label for AndroGel 1.62% requires monitoring of serum testosterone 14 days after initiation and dose adjustment to target a range of 400-700 ng/dL [3]. Including planned monitoring intervals in the PA request demonstrates that prescribing aligns with FDA-approved usage, which most BCBS plans require as a condition of coverage [3].

How to Appeal a BCBS Federated Denial of AndroGel

Denials happen even with complete documentation. A first-level internal appeal overturns a meaningful percentage of initial denials when the physician submits new or clarifying clinical information. The following framework reflects the standard BCBS appeal process for pharmacy benefits.

Step 1. Request the Denial Letter and Coverage Determination. BCBS is required under the ACA to provide a written explanation of the denial reason, the specific criteria not met, and instructions for appeal. This letter must arrive within 72 hours for urgent situations or 15 days for standard PA denials [8].

Step 2. File a First-Level Internal Appeal Within 180 Days. Most BCBS commercial plans allow 180 days from the date of the denial to file an internal appeal. FEP plans follow federal employee benefit timelines, which may differ. The appeal must include a physician-authored letter addressing each denial reason by name, updated lab results if the original values were more than 60 days old, and any peer-reviewed literature directly supporting the medical necessity of AndroGel over the step-therapy alternative. Citing the T-Trials [10] and the Endocrine Society guideline [1] in this letter is appropriate.

Step 3. Request Expedited Review If Medically Urgent. If delayed treatment poses a serious risk to health (for example, a patient with osteoporosis and documented hypogonadism at fracture risk), the appeal can be designated urgent. BCBS is required to respond to urgent internal appeals within 72 hours under federal mental health parity and ERISA rules [8].

Step 4. File a Second-Level Internal Appeal or Escalate Externally. If the first internal appeal fails, most BCBS plans offer a second internal review before external review. After internal options are exhausted, the member has the right to an Independent Medical Review (IMR) through the state insurance commissioner's office or, for FEP plans, through OPM's appeals process. External reviewers are independent of the insurer and overturn insurer decisions in a significant proportion of cases involving FDA-approved drugs with documented clinical criteria [8].

Step 5. Consider a Peer-to-Peer Review Before the Formal Appeal. Many BCBS PA teams allow the prescribing physician to request a peer-to-peer call with the plan's medical director before a formal denial is finalized, or within 5 business days after a denial. This call often resolves denials faster than the written appeal pathway and costs nothing.

Manufacturer Savings Programs and Cash-Pay Alternatives

AbbVie offers an AndroGel savings card program for commercially insured patients. As of 2024, eligible patients with commercial insurance (not Medicare or Medicaid) may pay as little as $0 to $30 per fill through the AbbVie Assist program [12]. The card cannot be used with federal insurance programs, and BCBS FEP plans administered under the Federal Employee Program are considered federal benefit plans for this purpose. Members on FEP should confirm eligibility directly with AbbVie at 1-800-633-9110 before relying on the savings card.

For patients who cannot obtain coverage or find the brand-name cost prohibitive, generic testosterone gel 1% (manufactured by Perrigo and others) offers the same active molecule at a fraction of the cost. A 30-day supply of generic testosterone gel at a 50 mg/day dose costs approximately $30-$60 at GoodRx pricing as of mid-2025 [7]. Testosterone cypionate 200 mg/mL injection, another generic option, delivers equivalent clinical results for most hypogonadal men and costs under $50 for a 10-mL vial [7]. The Endocrine Society states that "transdermal testosterone preparations are preferred in older men due to ease of dose adjustment," but injection formulations are clinically appropriate for most patients who tolerate them [1].

Monitoring Requirements That Keep Coverage Active After Approval

BCBS plans that approve AndroGel typically attach ongoing coverage conditions to the authorization. Most authorizations last 12 months and require re-authorization annually with updated lab values. Specifically, plans want to see serum testosterone levels in the target range of 400-700 ng/dL (mid-normal for most adult males), a hematocrit below 54% (to screen for polycythemia, a known testosterone adverse effect), and PSA values stable or below 4.0 ng/mL [4].

A study in the Journal of Clinical Endocrinology and Metabolism (N=1,176) found that approximately 15% of men on testosterone therapy develop a hematocrit above 52% within the first 12 months, and that this rate is higher with injectable formulations than with transdermal gels [13]. This pharmacokinetic difference is one clinical argument for AndroGel over injections in patients with borderline elevated baseline hematocrit, and it can be raised in both the initial PA and any appeal as a specific medical reason the brand gel is necessary rather than merely preferred.

The FDA updated the AndroGel label in 2014 to add a cardiovascular warning following the Basaria et al. trial (N=209, published in NEJM 2010), which found a higher rate of cardiovascular events in testosterone-treated men with mobility limitations [14]. BCBS PA reviewers are aware of this warning. The prescribing physician should document baseline cardiovascular risk (using a tool like the ACC/AHA 10-year ASCVD calculator) in any PA submission for patients aged 55 or older.

Confirmed Serum Testosterone Targets During Treatment

Once AndroGel is approved and initiated, maintaining testosterone in the target range is both clinically important and an insurance requirement for continued coverage. The Endocrine Society guideline recommends targeting the mid-normal range, approximately 400-700 ng/dL for most adult men, with a maximum acceptable level of 750 ng/dL on standard once-daily dosing [1]. Levels above 1 to 000 ng/dL on AndroGel 1.62% should prompt a dose reduction per the FDA label [3].

Serum testosterone should be measured 14 days after initiation (or after any dose change) as a trough level, drawn in the morning before the daily gel application. BCBS re-authorization forms routinely ask for the most recent serum testosterone value and the date it was drawn. Submitting values drawn at the wrong time of day (afternoon draws are typically 20-25% lower than morning values due to diurnal variation) may result in unnecessary dose escalation or a plan determination that therapy is not providing adequate response [1].

A direct morning testosterone draw showing a level of 450 ng/dL at the 14-day mark on AndroGel 1.62% 40.5 mg/day, documented with a lab report timestamped before 10 a.m., is the single most persuasive piece of re-authorization evidence a physician can submit [3].